SPY335.84-2.98 -0.88%
DIA279.57-1.46 -0.52%
IXIC10,910.28-140.19 -1.27%

Cantor Fitzgerald Reiterates Overweight on Cara Therapeutics, Raises Price Target to $40

Cantor Fitzgerald reiterates Cara Therapeutics (NASDAQ:CARA) with a Overweight and raises the price target from $34 to $40.

Benzinga · 05/19/2020 11:27

Cantor Fitzgerald reiterates Cara Therapeutics (NASDAQ:CARA) with a Overweight and raises the price target from $34 to $40.